Saturday, October 25, 2025 | 5:00 - 10:00 PM
Southern Exchange Ballrooms | Atlanta, Georgia
We return to Atlanta for the 2025 debra of America Gala to reflect on the extraordinary strides made in advancing research, care, and support for those affected by Epidermolysis Bullosa (EB). This special night honors the strength and resilience of the EB Community and reaffirms our continued commitment to improving the lives of individuals and families living with this rare and challenging condition.
This year’s Gala comes at a transformative moment. With three FDA-approved treatments for EB now available, there is more hope than ever for individuals and families living with EB. These historic milestones are the result of decades of dedication—from individuals and families affected by EB, to the researchers, clinicians, and industry partners working tirelessly to bring meaningful treatments to life.
The evening will feature a Casino Night theme, inviting guests to experience the excitement of the tables—all in support of our mission. Guests will also enjoy cocktails and hors d’oeuvres, a silent auction, an awards ceremony and a seated dinner.
Proceeds from the Benefit will go directly towards supporting people living with EB, a painful, often fatal, and always debilitating rare genetic disease.
What is Epidermolysis Bullosa (EB)?
Epidermolysis Bullosa (or EB, for short) - "The Worst Disease You've Never Heard Of" - is a group of rare disorders caused by a mutation in one of 18 genes. People with EB share the lifelong challenge of extremely fragile skin that blisters and tears from minor friction or trauma. The list of medical complications EB causes may be long and often requires multiple interventions from a range of medical specialists. EB is always painful, often pervasive and debilitating, and is in some cases lethal before the age of 30.
While there is still no cure for Epidermolysis Bullosa (EB), hope is no longer out of reach. Thanks to decades of tireless work and collaboration, treatments are now available that help ease some of the most painful and debilitating symptoms of certain types of EB. As of 2025, three therapies have been approved by the U.S. Food & Drug Administration—marking a historic shift in the landscape of care and a powerful step forward for individuals and families affected by this devastating disease.
There are about 25,000 people living with EB in the US. It occurs in every racial and ethnic group and affects both genders equally. Click here for a more in-depth and comprehensive understanding of EB.
About debra of America
debra of America's mission is to improve the lives of those impacted by Epidermolysis Bullosa (EB) — “The Worst Disease You’ve Never Heard Of.” We integrate direct-to-patient programs and services, education, advocacy, close partnership with treatment developers, and research funding to foster meaningful change for those living with EB.
Each year, debra of America spends an average of $1.5 million on direct-to-patient programs and services to provide immediate relief to thousands of families across the country. Our research funding identified the genetic basis of EB and supports the science, which is at the forefront of gene and stem cell therapy, RNA repair, protein replacement, and inhibition of squamous cell carcinoma.
Become a Sponsor
For questions or for more information about Sponsorship and Ad Opportunities, please call 212-868-1573 x102 or email events@debra.org.
Press & Media
For press & media inquiries for the 2025 debra of America Gala, please email events@debra.org.
Questions?
Please email events@debra.org or call 212-868-1573 x102.
Related Resources
Our Mission
“Because the cost of doing nothing is too great” is an axiom that defines our mission and directs all of debra of America’s actions as an organization.
Learn More
Donate
Make a tax-deductible gift that directly impacts the thousands living with "the worst disease you've never heard of."
Learn More
Video Stories
See Epidermolysis Bullosa (EB) up close and personal in the video stories of individuals impacted by EB.
Learn More
